References
- Li E , ZhangY. DNA methylation in mammals. Cold Spring Harb. Perspect. Biol.6(5), a019133 (2014).
- Sharma S , KellyTK , JonesPA. Epigenetics in cancer. Carcinogenesis31(1), 27–36 (2010).
- Shen H , LairdPW. Interplay between the cancer genome and epigenome. Cell153(1), 38–55 (2013).
- Yang M , ParkJY. DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol. Biol.863, 67–109 (2012).
- Chan AO , BroaddusRR , HoulihanPSet al. CpG island methylation in aberrant crypt foci of the colorectum. Am. J. Pathol.160(5), 1823–1830 (2002).
- Rashid A , ShenL , MorrisJSet al. CpG island methylation in colorectal adenomas. Am. J. Pathol.159(3), 1129–1135 (2001).
- Toth K , SiposF , KalmarAet al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One7(9), e46000 (2012).
- O’connell JB , MaggardMA , KoCY. Colon cancer survival rates with the New American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst.96(19), 1420–1425 (2004).
- Ashktorab H , BrimH. DNA methylation and colorectal cancer. Curr. Colorectal Cancer Rep.10(4), 425–430 (2014).
- Wojdacz TK , DobrovicA. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res.35(6), e41 (2007).
- Hauptman N , JevsinekSkok D , SpasovskaE , BostjancicE , GlavacD. Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4, and KCNA5 as potential diagnostic biomarkers in colorectal cancer. BMC Med. Genom.12(1), 54 (2019).
- Nazemalhosseini Mojarad E , KuppenPJet al. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol. Hepatol. Bed. Bench6(3), 120–128 (2013).
- Lao VV , GradyWM. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol.8(12), 686–700 (2011).
- Toyota M , AhujaN , Ohe-ToyotaMet al. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA96(15), 8681–8686 (1999).
- Grady WM . CIMP and colon cancer gets more complicated. Gut56(11), 1498–1500 (2007).
- Kim H , WangX , JinP. Developing DNA methylation-based diagnostic biomarkers. J. Genet. Genomics45(2), 87–97 (2018).
- Leygo C , WilliamsM , JinHCet al. DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer. Dis. Markers2017, 3726595 (2017).
- Wood LD , ParsonsDW , JonesSet al. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
- Simon K . Colorectal cancer development and advances in screening. Clin. Interv. Aging.11, 967–976 (2016).
- Bock C , HalbritterF , CarmonaFJet al. BLUEPRINT consortium. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. Nat. Biotechnol.34(7), 726–737 (2016).
- Jin B , LiY , RobertsonKD. DNA methylation: superior or subordinate in the epigenetic hierarchy?Genes Cancer2(6), 607–617 (2011).
- Kalari S , PfeiferGP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv. Genet.70, 277–308 (2010).
- Kok-Sin T , MokhtarNM , AliHassan NZet al. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncol. Rep.34(1), 22–32 (2015).
- Campregher PV , HamerschlakN. Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice. Clin. Lymphoma Myeloma Leuk.14(4), 271–276 (2014).
- Fernandez-Rozadilla C , PallesC , Carvajal-CarmonaLet al. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern European populations. Carcinogenesis34(2), 314–318 (2013).
- Miura T , IshiguroM , IshikawaTet al. Methylation of bone morphogenetic protein 2 is associated with poor prognosis in colorectal cancer. Oncol. Lett.19(1), 229–238 (2020).
- Yamashita M , ToyotaM , SuzukiHet al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer. Sci.101(7), 1708–1716 (2010).
- Palaniappan A , RamarK , RamalingamS. Computational Identification of novel stage-specific biomarkers in colorectal cancer progression. PloS One11(5), e0156665–e0156665 (2016).
- Liu Y , WangS-Q , LongY-Het al. KRASG12 mutant induces the release of the WSTF/NRG3 complex, and contributes to an oncogenic paracrine signaling pathway. Oncotarget7(33), 53153–53164 (2016).
- Okazaki S , IshikawaT , IidaSet al. Clinical significance of UNC5B expression in colorectal cancer. Int. J. Oncol.40(1), 209–216 (2012).
- Thiebault K , MazelinL , PaysLet al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc. Natl. Acad. Sci. USA100(7), 4173–4178 (2003).
- Liu L , ChenY , ZhangQ , LiC. Silencing of KCNA1 suppresses the cervical cancer development via mitochondria damage. Channels13(1), 321–330 (2019).